CVCapsoVision, Inc.

1. Sep 28, 2026On September 28, 2026, the Company announced that AI Highlights™, its AI-assisted reading feature for the CapsoCam Plus® system, received clearance from the U.S. Food and Drug Administration on September 25, 2026.Other event · Form 8-K
2. Sep 18, 2026On September 17, 2026, CapsoVision, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors (the “Purchasers”), which provides for the issuance and sale, in a registered direct offering by the Company, of an aggregate of 3,163,444 shares (the “Shares”) of its …Material agreement entered · Form 8-K
3. Aug 18, 2026As previously announced, on August 13, 2026, CapsoVision, Inc. (the “Company”) entered into a Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole …Other event · Form 8-K
4. Aug 13, 2026On August 13, 2026, CapsoVision, Inc. (the “Company”) entered into a Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion …Material agreement entered · Form 8-K
5. Jul 2, 2026Appointment of Dr. David S. Shields as a Director On July 1, 2026, the Board of Directors (the “Board”) of CapsoVision Inc. (the “Company”) appointed Dr. David Stanley Shields to serve as a Class I director of the Board and as a member of the Compensation Committee of the Board, in each case effective immediately to …Director or officer change · Form 8-K
6. May 14, 2026CapsoVision Reports First Quarter 2026 Financial Results.Earnings release · press release
7. Mar 26, 2026CapsoVision Reports Fourth Quarter and Full Year 2025 Financial Results.Earnings release · press release
8. Mar 20, 2026On March 16, 2026, CapsoVision, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with selected accredited investors (the “Investors”), for the purposes of raising approximately $14 million in aggregate gross proceeds for the Company (the “Private Placement”)Material agreement entered · Form 8-K
9. Mar 13, 2026As previously reported on Form 8-K filed by CapsoVision, Inc. (the “Company”) on July 15, 2026 (the “July 15th 2025 8-K”), the Company entered into a development agreement (the “Agreement”) with Canon Inc., a Japanese corporation (“Canon”), for the development of complementary metal-oxide-semiconductor (“CMOS”) image …Material agreement entered · Form 8-K
10. Dec 29, 2025CapsoVision Announces 510(k) Submission for the Addition of AI-Assisted Reading Module in CapsoCam Plus®.Other event · press release
11. Nov 13, 2025CapsoVision Reports Third Quarter 2025 Financial Results.Earnings release · press release

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.